Daxor Accelerates Commercial Expansion of Next-Gen Blood Volume Diagnostic Platform at MedAxiom CV Transforum Fall '26
Daxor will showcase its next-generation, FDA 510(k)-cleared Blood Volume Analyzer platform at the MedAxiom CV Transforum Fall '26 conference in Denver, October 22-24, 2026. The new platform operates 3x faster than its predecessor, requires 50% less sample volume, and delivers greater than 95% measurement accuracy.
Key figures
- Accuracy
- >95%
- Speed improvement
- 3x faster than predecessor
- Sample volume reduction
- 50% less sample volume
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.